Inspirna is a biotechnology company utilizing its proprietary RNA-DRIVEr™ platform to identify and target previously unknown drivers of metastasis in common cancers with small molecules and biologics. The company aims to transform these cancers into manageable conditions by developing first-in-class oral therapeutics that enhance patient survival while maintaining quality of life.
Funding
$55.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SCVCFounders
Product
Problem
Many common cancers develop resistance to existing treatments due to previously unknown drivers of metastasis. These cancers often become unmanageable, leading to decreased patient survival and reduced quality of life. There is a need for novel therapeutics that can effectively target these previously untreatable cancers.
Solution
Inspirna is developing first-in-class oral therapeutics that target previously unknown drivers of metastasis in common cancers, aiming to transform these cancers into manageable conditions. The company utilizes its proprietary RNA-DRIVEr™ platform to identify and validate these novel drug targets. Their approach focuses on developing small molecules and biologics that enhance patient survival while maintaining quality of life. Inspirna's pipeline includes therapies in clinical development for RAS mutant colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and endometrial cancer.
Target Audience
The primary target audience includes patients with RAS mutant colorectal cancer, non-small cell lung cancer, and other cancers with high unmet medical needs, as well as the physicians treating these patients.
Features
- RNA-DRIVEr™ platform for identifying and validating novel cancer drivers
- Ompenaclid (RGX-202): An oral small molecule inhibitor of SLC6A8, inducing apoptosis in colorectal cancer cells, currently in Phase 2 clinical trials.
- Abequolixron (RGX-104): An oral small molecule activator of LXR/APOE, inhibiting tumor angiogenesis and enhancing the immune response against tumors, currently in Phase 1b/2 clinical trials.
- RGX-019: A monoclonal antibody-drug conjugate (ADC) targeting MERTK to selectively kill cancer cells and activate tumor myeloid cells, currently in preclinical development.
- Development of therapies with oral dosing and safety profiles designed for seamless integration with existing standard-of-care treatments.